Monoclonal antibody therapy for COVID-19 – Part 2

Last November, the FDA released an Emergency Use Authorization (EUA) for the use of monoclonal antibody therapy for adult and pediatric patients with mild to moderate COVID-19. Currently, there is some confusion about the availability and access issues to these treatment options.


In this episode, part two of a three-part series, we will address questions and concerns about the distribution and availability of these therapies.


Guest speakers:
Azra Behlim, PharmD, MBA
Senior Director
Pharmacy Sourcing and Program Services 


Steve Rudner, PharmD, MS
Pharmacy Network Contracting


Tomas Villanueva, DO, MBA, FACPE, SFHM
Associate Vice President
Clinical Resources


Show Notes:
[02:05] Access to the monoclonal antibody therapies
[03:51] No lack of supply
[05:07] Infusion options
[09:59] Misconceptions and challenges around distribution
[11:40] Every idea worth exploring


Links | Resources:

Press release and information from FDA Click here

Information from FDA on EUA for monoclonal antibody therapy Click here

ASPR’s portfolio of COVID-19 medical countermeasures (HHS site) Click here

[ For more information, contact: ]

JAMA article: “An EUA for Bamlanivimab—A Monoclonal Antiboey for COVID-19” (Dec. 11, 2020) Click here


Subscribe Today!

Apple Podcasts



Google Podcasts


RSS Feed


Share | Download(Loading)

Episodes Date

Load more